Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …

Although cardiologists have long treated patients with coronary artery disease (CAD) and
concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a …

Chronic kidney disease, defined as a reduced glomerular filtration rate or increased urinary
albumin excretion, is recognised as a rapidly growing global health burden, and increasing …

Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute
ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their …

Vale salientar que níveis de evidência classificados como B ou C não podem ser
interpretados como recomendações fracas. Existem muitas recomendações consensuais …

Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …

Background: Patients with diabetes appear to be at elevated risk of atherothrombotic events.
Objectives: The purpose of this study was to determine the effect of antiplatelet therapy with …

Cardiovascular disease, particularly coronary artery dis-ease resulting from accelerated
atherosclerosis, is the leading cause of morbidity and mortality in patients with diabetes …

Objectives: This study sought to investigate the evolving pattern over time of on-clopidogrel
platelet reactivity (PR) and its relationship with genotype and clinical outcomes after …

Chronic kidney disease (CKD) is an independent risk factor for coronary artery disease
(CAD). Coronary artery disease is the leading cause of morbidity and mortality in patients …